Therapeutic Uses
Anti-Thrombotics
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
5-(2-(Cyclopropyl-2,2,3,3-d4)-1-(2-fluorophenyl)-2-oxoethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Prasugrel-d4 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Prasugrel-d4 usage and description
Prasugrel D4 is a deuterated analog of Prasugrel, a thienopyridine antiplatelet agent used to prevent thrombotic events in patients with acute coronary syndromes. The deuterated form of Prasugrel, Prasugrel D4, is used primarily in clinical research studies to improve the accuracy of pharmacokinetic analysis and to ensure the consistency of study results.
Prasugrel D4 inhibits the activation of platelets by irreversibly binding to the P2Y12 receptor, which is involved in the ADP-mediated activation of platelets. This binding prevents the activation of the glycoprotein IIb/IIIa receptor and the subsequent aggregation of platelets, which can lead to the formation of thrombi. Prasugrel D4 is metabolized in the liver by cytochrome P450 enzymes to form its active metabolite, R-138727, which has a longer half-life than the parent compound and is responsible for most of the antiplatelet effects of Prasugrel D4.
The recommended dose of Prasugrel D4 is 60 mg once daily, taken orally with or without food. The drug is contraindicated in patients with a history of stroke, transient ischemic attack, or bleeding disorders, and caution should be exercised in patients with renal or hepatic impairment. Common side effects of Prasugrel D4 include bleeding, including life-threatening and fatal bleeding, and other adverse events such as angioedema, rash, and dyspnea. Overall, Prasugrel D4 is an effective and well-tolerated antiplatelet agent that is used in clinical research studies to improve the accuracy and consistency of study results.
